It is going into the hands of shareholders?
"But note that Pfizer, Merck, AbbVie, and Amgen have each announced $10 billion buyback plans, which is a larger sum for each of them than than any of their total R&D budgets." [https://www.science.org/content/blog-post/s-all-money-going-pharma-edition](https://www.science.org/content/blog-post/s-all-money-going-pharma-edition)


Partially R&D, partially into buy backs or shareholders:
[https://www.healthaffairs.org/do/10.1377/hblog20170307.059036/full/](https://www.healthaffairs.org/do/10.1377/hblog20170307.059036/full/) - the premium gained from just higher prices in US are about 76% of R&D costs, so 40 billion is going somewhere in a 325 billion dollar industry

If you watch television, you know part of the answer to where this extra money is going: sales and advertising. Of the 10 largest pharmaceutical companies, only one [spends more](https://www.bbc.com/news/business-28212223) on research than on marketing its products. - maybe this is because you HAVE to be a public company to be a successful drug company since you need so much access to liquidity, and public markets have such strong pressures to make short term gains
